CDR-Life Inc. has reported preclinical data for the CDR-813, a novel antibody fragment-based bivalent T-cell engager targeting preferentially expressed antigen in melanoma (PRAME) on HLA-A*02:01.

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape ...

The other heavy chain of the vaguely Y-shaped antibody targets CD38, another myeloma target. Binding to all three targets brings the T cell and the tumor together, Konto said. From there ...

Learn about common mistakes in manual ELISA assays and discover how automation can eliminate errors, improving accuracy, ...

RNA modulates transcription factor binding to DNA, though the subsequent effect on transcription remains unclear. The study ...

Historically, most of the clinical associations of myositis specific antibodies (MSAs) and myositis associated antibodies (MAAs) have been established using IP. Consequently, it is important to ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

An example of targeted therapy is antibody-drug conjugates (ADCs), which are designed to deliver a cancer-killing ...